Abstract

Background

Mefloquine (MQ) is an important antimalarial drug. Dizziness and other adverse neuropsychiatric reactions have however restricted its use.

Method

Ten healthy adult volunteers were given MQ (Lariam) 250 mg once weekly for 16 weeks. Measurement of postural sway (posturography), nystagmus recording, determinations of hearing thresholds (Bekesy audiometry), and determinations of drug concentrations were done before, after 4, 32, and 109 days of weekly MQ intake and 3 months after the last dose.

Results

All volunteers were able to continue their professional work and normal daily activities. Several mild symptoms were reported. In at least one of the volunteers, these symptoms were probably caused by the MQ intake. Hearing thresholds remained normal. No significant changes were noted in the nystagmus tests. The recorded values of sway index were within the normal range (99% confidence interval) in all volunteers in all test situations, and no differences were seen at the time of maximal drug concentrations (day 109) compared to before or after the study. There was no correlation between the plasma concentrations of MQ, the two MQ enantiomers (RS and SR), or the main mefloquine metabolite and the sway index.

Conclusion

Although no effect was seen on the vestibular system in the present study, further tests in a flight simulator will be needed before MQ can be recommended for pilots.

References

1
Rouveix
B
Bricaire
F
Michon
C
, et al.
Mefloquine and an acute brain syndrome
.
Ann Intern Med
 
1989
;
110
:
577
578
.
2
World Health Organization. Central nervous system reactions related to the antimalarial drug mefloquine.
Internal Document WHO/MAL/89/1054
. Geneva :
World Health Organization
,
1989
.
3
Bem
JL
Kerr
L
Stürchler
D.
Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions
.
J Trop Med Hyg
 
1992
;
85
:
208
209
.
4
World Health Organization. Advances in malaria chemotherapy.
Technical Report Series
No.
711
. Geneva :
World Health Organization
,
1984
.
5
Lobel
H
Miani
M
Eng
T
, et al.
Long-term prophylaxis with weekly mefloquine
.
Lancet
 
1993
;
341
:
848
851
.
6
Steffen
R
Fuchs
E
Schildknecht
J
, et al.
Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa
.
Lancet
 
1993
;
341
:
1299
1303
.
7
World Health Organization.
International travel and health
. Geneva :
World Health Organization
,
1994
.
8
Bergenius
J
Magnusson
M.
The relationship between caloric response, oculomotor defects, and the size of cerebellopontino angle tumors
.
Acta Otolaryngol
 
1988
;
106
:
361
367
.
9
Bergqvist
Y
Hellgren
U
Churchill
FC.
High performance liquid chromatographic assay for the simultaneous monitoring of mefloquine and its acid metabolite in biological samples using protein precipitation and ion-pair extraction
.
J Chromatogr
 
1988
;
432
:
253
263
.
10
Bergqvist
Y
Doverskog
M
Kabbani
J.
High performance liquid chromatographic determination of (SR) and (RS) enantiomers of mefloquine in plasma and capillary blood samples on paper after derivatization with (-)-1-(9-fluorenyl) ethyl chloroformate
.
J Chromatogr
 
1994
;
652
:
73
81
.
11
Ledin
T
Ödkvist
LM.
Effect of alcohol measured by dynamic posturography
.
Acta Otolaryngol
 
1991
;
481
:
576
581
.
12
Gupta
A
Ledin
T
Larsen
LE
, et al.
Computerized dynamic posturography: a new method for the evaluation of postural stability following anaesthesia
.
Br J Anaesth
 
1991
;
66
:
667
672
.
13
Robin
D
Hasan
S
Lichtenstein
M
, et al.
Dose-related effect of triazolam on postural sway
.
Clin Pharmacol Ther
 
1991
;
49
:
581
588
.
14
Karbwang
J
White
N.
Clinical pharmacokinetics of mefloquine
.
Clin Pharmacokinet
 
1990
;
19
:
264
279
.
15
Patchen
L
Campbell
C
Williams
S.
Neurological reactions after a therapeutic dose of mefloquine
.
N Engl J Med
 
1989
;
321
:
1415
.
16
Stürchler
D
Handschin
J
Kaiser
D
, et al.
Neuropsychiatric side effects of mefloquine
.
N Engl J Med
 
1990
;
322
:
1752
1753
.
The study was supported by Hoffman LaRoche, Basel Switzerland and grants from SAREC (Swedish Agency for Research Cooperation with Developing Countries—SWE 93-223).